Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 19.5 mg intrauterine system for intrauterine use. It provides long‑acting hormonal contraception by releasing levonorgestrel directly into the uterine cavity, thereby preventing pregnancy in women of reproductive age. It works through multiple mechanisms that affect sperm function and the endometrium.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each shipment.

Kyleena, a levonorgestrel‑based intrauterine system, is indicated for hormonal contraception.

Contraception (prevention of pregnancy): Provides highly effective, reversible birth control for up to five years in women of reproductive age.

Kyleena may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular menstrual bleeding or spotting - Amenorrhea (absence of periods) - Headache - Breast tenderness - Mood changes - Abdominal or pelvic pain

Serious or Rare Side Effects: - Pelvic inflammatory disease - Uterine perforation during insertion - Ectopic pregnancy - Severe allergic reaction (anaphylaxis)

Before using Kyleena, consider the following precautions.

Pregnancy testing: Ensure the patient is not pregnant before insertion. Uterine abnormalities: Evaluate for fibroids, congenital anomalies, or scarring. Recent pelvic infection: Treat any active infection prior to placement. Breastfeeding: Discuss benefits and risks with the prescriber. Follow‑up: Schedule post‑insertion check to confirm correct positioning. Store at ambient temperature: Keep in original packaging, protect from moisture and direct sunlight.

Kyleena may interact with other medications that affect hormonal balance or uterine environment.

Major Interactions (Avoid): - Anticonvulsants (e.g., carbamazepine, phenytoin): May reduce levonorgestrel effectiveness. - Rifampin or other enzyme‑inducing antibiotics: Can lower hormone levels.

Moderate Interactions (Monitor Closely): - Hormonal therapies (e.g., estrogen‑containing contraceptives): May increase risk of thromboembolic events. - Antifungal agents (e.g., ketoconazole): Potentially increase levonorgestrel concentrations. - Herbal supplements (e.g., St. John’s wort): May alter hormone metabolism.